GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Forward PE Ratio

MYGN (Myriad Genetics) Forward PE Ratio : 119.92 (As of Dec. 12, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Forward PE Ratio?

Myriad Genetics's Forward PE Ratio for today is 119.92.

Myriad Genetics's PE Ratio without NRI for today is 103.64.

Myriad Genetics's PE Ratio (TTM) for today is 0.00.


Myriad Genetics Forward PE Ratio Historical Data

The historical data trend for Myriad Genetics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Forward PE Ratio Chart

Myriad Genetics Annual Data
Trend 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-12 2022-12 2023-01 2024-12
Forward PE Ratio
25.64 16.34 32.36 15.72 22.68 400.00 99.01 33.44 44.25 121.04

Myriad Genetics Quarterly Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03 2017-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2024-03 2024-06 2024-09 2024-12
Forward PE Ratio 25.64 19.08 16.08 18.62 16.34 17.45 23.26 34.60 32.36 22.37 27.70 26.46 15.72 19.53 16.34 15.22 22.68 14.79 10.91 15.55 400.00 66.67 119.05 99.01 23.47 14.81 13.53 33.44 2,000.00 833.33 454.55 121.04

Competitive Comparison of Myriad Genetics's Forward PE Ratio

For the Diagnostics & Research subindustry, Myriad Genetics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Forward PE Ratio falls into.



Myriad Genetics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Myriad Genetics  (NAS:MYGN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Myriad Genetics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Paul J Diaz director, officer: President and CEO 680 SOUTH FOURTH STREET, LOUISVILLE KY 40202
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Reitan Colleen F director 300 THIRD STREET, CAMBRIDGE MA 02142
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116